Nation's Leading Organization on AD/HD Poised to Continue Moving Forward with Passionate Advocacy Agenda
Landover, MD -- CHADD, the nation's leading advocacy organization serving children and adults with Attention Deficit/Hyperactivity Disorder (AD/HD), today stands vindicated that United States District Judge Hilda G. Tagla dismissed a lawsuit filed in Texas against CHADD, the American Psychiatric Association (APA) and Novartis, manufacturer of Ritalin. The lawsuit claimed that the three organizations conspired together to promote the use of Ritalin for financial gain.
Judge Tagla announced her decision late Thursday, May 17, with prejudice, claiming that the allegations were fully without merit. Defendants failed to provide any concrete statements to document their claims, which the Judge described as failure "to plead with particularity."
"Judge Tagla's dismissal speaks volumes about the irresponsible actions of those who filed suits against CHADD," said CHADD Chief Executive Officer E. Clarke Ross. "Today we stand in an even stronger position to continue sharing with the public the evidence-based, science-based information that is core to CHADD's mission."
Judge Tagla's decision came two months on the heels of a similar dismissal in California where Senior U.S. District Judge Rudi Brewster dismissed a complaint against CHADD confirming that the plaintiffs had failed to provide any substantiation for their allegations. Although the plaintiffs were given an opportunity to cure this deficiency with an amended complaint to be filed no later than April 16, 2001, they failed to do so. Judge Brewster then reaffirmed his previous ruling dismissing the case, and entered a new order requiring the plaintiffs to pay the legal fees incurred by the defendants including CHADD.
"That such absurd accusations even found their way into court despite the extraordinary amount of science-based research clearly proving the disorder's existence-is just one example of the kind of hostility and skepticism that individuals with AD/HD face each day.""That such absurd accusations even found their way into court-despite the extraordinary amount of science-based research clearly proving the disorder's existence-is just one example of the kind of hostility and skepticism that individuals with AD/HD face each day," said CHADD President Beth Kaplanek. "The Texas and California decisions demonstrate the validity and seriousness of AD/HD, the ridiculous grounds of the complaints, and the important role that CHADD's advocacy efforts play in serving those with AD/HD."
CHADD advocates a multimodal approach to the treatment of AD/HD including parent training in diagnosis, treatment and specific behavior management techniques, an appropriate educational program, individual and family counseling when needed, and medication when required.
Attention-Deficit/Hyperactivity Disorder (AD/HD) is characterized by developmentally inappropriate impulsivity, attention, and in some cases, hyperactivity. AD/HD is a neurobiological disability that affects three-to-five percent of school-age children and approximately two-to-four percent of adults.
With over 22,000 members in 225 affiliates nationwide, CHADD works to improve the lives of people affected by AD/HD through collaborative leadership, advocacy, research, education and support: CHADD CARES. For additional information about AD/HD or CHADD, please contact CHADD National Call Center at 1-800-233-4050, or visit the CHADD website at www.chadd.org.
339 East Ave. Suite 420, Rochester, New York 14604.
e-mail us at email@example.com
Return to GRADDA Newsletter Table of Contents Page
Return to GRADDA Home Page